Lv1
40 积分 2021-08-18 加入
Perioperative or postoperative adjuvant oxaliplatin with S-1 versus adjuvant oxaliplatin with capecitabine in patients with locally advanced gastric or gastro-oesophageal junction adenocarcinoma undergoing D2 gastrectomy (RESOLVE): final report of a randomised, open-label, phase 3 trial
1个月前
已完结
Perioperative or postoperative adjuvant oxaliplatin with S-1 versus adjuvant oxaliplatin with capecitabine in patients with locally advanced gastric or gastro-oesophageal junction adenocarcinoma undergoing D2 gastrectomy (RESOLVE): final report of a randomised, open-label, phase 3 trial
1个月前
已完结
Emerging insights into natural killer cells in human peripheral tissues
4个月前
已完结
A novel triple-knockout allogeneic BCMA CAR T cell therapy (CT0590) in multiple myeloma: preclinical and phase I study
5个月前
已完结
How I treat HLH-like toxicities after immune effector cell therapy
5个月前
已完结
Type I interferon inhibitor anifrolumab in active systemic lupus erythematosus (TULIP-1): a randomised, controlled, phase 3 trial
7个月前
已完结
Teclistamab plus Daratumumab in Relapsed or Refractory Multiple Myeloma
7个月前
已完结
A practical Bayesian design to identify the maximum tolerated dose contour for drug combination trials
8个月前
已完结
Bayesian optimal interval design for dose finding in drug-combination trials
8个月前
已完结
Glofitamab plus gemcitabine and oxaliplatin (GemOx) versus rituximab-GemOx for relapsed or refractory diffuse large B-cell lymphoma (STARGLO): a global phase 3, randomised, open-label trial
8个月前
已完结